Public health advocates and healthcare professionals (HCPs) have been challenged with vaccine hesitancy and addressing misinformation. In order for HCPs and pharmacists, in particular, to serve as effective stewards of COVID-19 vaccine science in the interest of the public good, it is imperative for HCPs to appreciate the various factors contributing to vaccine hesitancy and vaccine distrust. A PubMed search was performed and relevant articles on COVID-19 vaccine in populations of interest were included. Information from health agencies, such as the Centers for Disease Control and Prevention (CDC) as well as established professional health societies was incorporated for guidance. This review focuses on COVID-19 vaccine concerns in the populations of children, pregnancy and lactation, immunocompromised, and religious and ethnic disparities. We also discuss post emergency use authorization experience with respect to vaccine safety including annotations on Guillain-Barré Syndrome, myocarditis and pericarditis, and thrombosis with thrombocytopenia syndrome.
WolfeRMSharpLK.Anti-vaccinationists past and present. BMJ. 2002;325(7361):430-432.
2.
AlbertMROstheimerKGBremanJG.The last smallpox epidemic in Boston and the vaccination controversy, 1901-1903. N Engl J Med. 2001;344(5):375-379.
3.
WalterEBTalaatKRSabharwalC, et al.; C4591007 Clinical Trial Group. Evaluation of the BNT162b2 covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. Published online November 9, 2021. doi:10.1056/NEJMoa2116298
4.
GrayKJBordtEAAtyeoC, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021;225(3):303.e1-303.e17.
5.
AghaMEBlakeMChilleoCWellsAHaidarG.Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era. Open Forum Infect Dis. 2021;8(7):ofab353.
6.
BoyarskyBJWerbelWAAveryRK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325(17):1784-1786.
7.
MackeyKAyersCKKondoKK, et al. Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review. Ann Intern Med. 2021;174(3):362-373.
8.
MudeWOguomaVMNyanhandaTMwanriLNjueC.Racial disparities in COVID-19 pandemic cases, hospitalisations, and deaths: a systematic review and meta-analysis. J Glob Health. 2021;11:05015.
9.
Abdul-MutakabbirJCCaseySJewsV, et al. A three-tiered approach to address barriers to COVID-19 vaccine delivery in the black community. Lancet Glob Health. 2021;9(6):e749-e750.
10.
ShimabukuroTTKimSYMyersTR, et al. Preliminary findings of mRNA covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021;385(16):1536.
11.
VinerRMMyttonOTBonellC, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021;175(2):143-156.
FeldsteinLRTenfordeMWFriedmanKG, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021;325(11):1074-1087.
17.
RabinowiczSLeshemEPessachIM.COVID-19 in the pediatric population-review and current evidence. Curr Infect Dis Rep. 2020;22(11):29.
18.
CooperDMAfghaniBByingtonCL, et al. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges. Pediatr Res. 2021;24:1-5.
U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine EUA letter of authorization. 2021. Accessed May 15, 2021. https://www.fda.gov/media/144412/download
KoJYDeSistoCLSimeoneRM, et al. Adverse pregnancy outcomes, maternal complications, and severe illness among U.S. delivery hospitalizations with and without a COVID-19 diagnosis. Clin Infect Dis. 2021;73(Suppl 1):S24-S31.
23.
Society for Maternal Fetal Medicine. Provider considerations for engaging in COVID-19 vaccine counseling with pregnant and lactating patients. 2021. Accessed August 18, 2021. https://www.smfm.org/covidclinical
24.
GoldshteinINevoDSteinbergDM, et al. Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women. JAMA. 2021;326:728-735. doi:10.1001/jama.2021.11035
MbaeyiSOliverSECollinsJP, et al. The Advisory Committee on Immunization practices’ interim recommendations for additional primary and booster doses of COVID-19 vaccines – United States, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1545-1552.
30.
Bar-OnYMGoldbergYMandelM, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393-1400.
31.
GambichlerTReutherJScheelCHBeckerJC.On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. J Immunother Cancer. 2020;8(2):e001145.
32.
AgrawalASTaoXAlgaissiA, et al. Immunization with inactivated middle east respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12(9):2351-2356.
33.
Lyons-WeilerJ.Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun. 2020;3:100051.
34.
BakerDRobertsCAKPryceG, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020;202(2):149-161.
35.
DayALWinthropKLCurtisJR.The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults. Cleve Clin J Med. 2020;87(11):695-703.
36.
RubinLGLevinMJLjungmanP, et al. IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-100.
37.
DagnewAFIlhanOLeeWS, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988-1000.
QuinnSCAndrasikMP.Addressing vaccine hesitancy in BIPOC communities—toward trustworthiness, partnership, and reciprocity. N Engl J Med. 2021;385(2):97-100.
42.
BajajSSStanfordFC.Beyond Tuskegee—vaccine distrust and everyday Racism. N Engl J Med. 2021;384(5):e12.
GrumbachKJudsonTDesaiM, et al. Association of race/ethnicity with likeliness of COVID-19 vaccine uptake among health workers and the general population in the San Francisco bay area. JAMA Intern Med. 2021;181(7):1008-1011.
50.
KennedyBRMathisCCWoodsAK.African Americans and their distrust of the health care system: healthcare for diverse populations. J Cult Divers. 2007;14(2):56-60.
51.
Abdul-MutakabbirJCCaseySJewsV, et al. A multifaceted approach to provide the equitable delivery of COVID-19 vaccines in the black community. European Congress of Clinical Microbiology and Infectious Diseases. Accepted Abstract. July 2021.
PRRI. Faith-based approaches can positively impact COVID-19 vaccination efforts: religious identities and the race against the virus. PRRI-IFYC. Published April 22, 2021. Accessed May 21, 2021. www.prri.org/research/prri-ifyc-covid-vaccine-religion-report/
54.
Institute of Medicine (US) Conference Committee on Fetal Research and Applications. Fetal Research and Applications: A Conference Summary. Setting the Stage: Fetal Research, Fetal Tissue Research, and Historical Timeline of Regulation and Legislation. National Academies Press; 1994. Accessed May 21, 2021. https://www.ncbi.nlm.nih.gov/books/NBK231997/
55.
WadmanM.Vaccines that use human fetal cells draw fire. Science. 2020;368(6496):1170-1171.
56.
PlotkinS.History of vaccination. Proc Natl Acad Sci U S A. 2014;111(34):12283-12287.
57.
U.S. Food and Drug Administration. Moderna COVID-19 Vaccine [Full Emergency Use Authorization (EUA) Prescribing Information]. Moderna US, Inc; 2021.
58.
J&J/Janssen Biotech Inc. Johnson & Johnson (J&J/Janssen) COVID-19 Vaccine [Full Emergency Use Authorization (EUA) Prescribing Information]. J&J/Janssen Biotech Inc; 2021.
MacNeilJRSuJRBroderKR, et al. Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients—United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021;70:651-656.
61.
Centers for Disease Control and Prevention. Cases of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Receipt of the Johnson & Johnson COVID-19 Vaccine. Health Alert Network (HAN). US Department of Health and Human Services, CDC; 2021.Accessed November 18, 2021. https://emergency.cdc.gov/han/2021/han00442.asp/
62.
ShayDKShimabukuroTTDeStefanoF.Myocarditis occurring after immunization with mRNA-Based COVID-19 vaccines. JAMA Cardiol. 2021;6:1115-1117. doi:10.1001/jamacardio.2021.2821
63.
MarshallMFergusonIDLewisP, et al. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021;148:e2021052478. doi:10.1542/peds.2021-052478
64.
GarganoJWWallaceMHadlerSC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on immunization practices – United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977-982.
65.
United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC) / Food and Drug Administration (FDA). Vaccine Adverse Event Reporting System (VAERS) 1990 - 07/30/2021, CDC WONDER On-line Database. Accessed August 12, 2021. http://wonder.cdc.gov/vaers.html
